作者
Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Hänni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos, Özgür Yaldizli
发表日期
2021/3
期刊
Journal of neurology
卷号
268
页码范围
941-949
出版商
Springer Berlin Heidelberg
简介
Background
Dimethyl fumarate and fingolimod are oral disease modifying treatments (DMTs) that reduce relapse activity and slow disability worsening in relapsing–remitting multiple sclerosis (RRMS).
Objective
To compare the effectiveness of dimethyl fumarate and fingolimod in a real-world setting, where both agents are licensed as a first-line DMT for the treatment of RRMS.
Methods
We identified patients with RRMS commencing dimethyl fumarate or fingolimod in the Swiss Federation for Common Tasks of Health Insurances (SVK) Registry between August 2014 and July 2019. Propensity score-matching was applied to select subpopulations with comparable baseline characteristics. Relapses and disability outcomes were compared in paired, pairwise-censored analyses.
Results
Of …
学术搜索中的文章
J Lorscheider, P Benkert, C Lienert, P Hänni, T Derfuss… - Journal of neurology, 2021